09:58 AM EST - Theratechnologies Inc. : Has successfully completed a bioequivalence study evaluating a new formulation of tesamorelin compared to the original formulation approved by the U.S. Food and Drug Administration (F1). This new formulation, known as “F8”, is stable at room temperature for up to seven days after reconstitution and its volume of administration is only 0.16 mL (12.5 times smaller than the F1 and two times smaller than the current F4 formulation (EGRIFTA SV®), making it possible to have a single multidose vial containing seven days of treatment. The F8 is patent protected in the U.S. until 2033 and until 2034 in major European countries. Theratechnologies Inc.
shares T.TH are trading down $0.08 at $2.69.
